Pharma BD Deal Intelligence
The $3.9B AAA deal looked like a niche GEP-NET buy in 2017 but turned out to be the platform that produced Pluvicto — one of oncology's biggest launches of the decade, now tracking toward $5B+ peak sales.
Full analysis, sources & comparables →Novartis acquired AAA for $3.9B for nuclear medicine and radiopharmaceuticals.
Canaccord Genuity analyst John Newman called the deal 'highly synergistic' with Novartis's existing Sandostatin/Afinitor NET franchise; Baader Helvea analyst…
BioPharma Dive noted Novartis closed the AAA deal 'just in time for the FDA's target decision date' — and that NETTER-1 had shown a 79% reduction in risk of…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Novartis announced a memorandum of understanding to acquire AAA via tender offer at $41/ordinary share ($82/ADS), valuing AAA equity at approximately $3.9B. The deal added Lutathera, a first-in-class lutetium-based peptide receptor radionuclide therapy for neuroendocrine tumors, plus AAA's molecular nuclear medicine manufacturing platform. The transaction was the entry point for Novartis's radioligand therapy franchise. Closed January 2018.
The $3.9B AAA deal looked like a niche GEP-NET buy in 2017 but turned out to be the platform that produced Pluvicto — one of oncology's biggest launches of the decade, now tracking toward $5B+ peak sales.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Advanced Accelerator Applications S.A. (this deal) | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2017 deals · Novartis AG deals · Neurology deals